Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review
Circulation: Population Health and Outcomes · 2026-07 · 19 (7)
DOI: 10.1161/circoutcomes.125.012989 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation: Population Health and Outcomes, 2026-07. Verfasst von Tristan J Alfie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston (T.J.A.). Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Angiotensin Receptor Antagonists, Stroke Volume. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors (ARNI) are heart failure (HF) therapies selected for price negotiations under the Inflation Reduction Act. This study aimed to summarize the cost-effectiveness of SGLT2 inhibitors and ARNIs for HF, examine how cost-effectiveness varies by ejection fraction (EF) and drug price, and estimate the effect of negotiated prices on cost-effectiveness. METHODS: A systematic literature search identified cost-effectiveness analyses of SGLT2 inhibitors and ARNIs versus standard of care for the treatment of HF from a US perspective, published through 2025. Analyses were stratified by HF with reduced EF (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Massachusetts General Hospital, Boston (T.J.A.).
- Department of Medicine, Harvard Medical School, Boston, MA (T.J.A., J.H.W., D.S.K., J.L.J., L.P.C.).
- Cardiology Division, Massachusetts General Hospital and Heart and Vascular Institute, Mass General Brigham, Boston (J.H.W., J.L.J., L.P.C.).
- Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (D.S.K.).
- Baim Institute for Clinical Research, Boston, MA (J.L.J.).
- Division of General Medicine, Columbia University Irving Medical Center, New York, NY (B.K.B.).
ORCID-Profile: Tristan J Alfie, Jason H Wasfy, Dhruv S Kazi, James L Januzzi, Brandon K Bellows, Laura P Cohen
Förderung
- NHLBI NIH HHS
Zitieren
APA
Alfie, T. J., Wasfy, J. H., Kazi, D. S., Januzzi, J. L., Bellows, B. K., & Cohen, L. P. (2026). Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review. Circulation: Population Health and Outcomes, 19(7). https://doi.org/10.1161/circoutcomes.125.012989
Vancouver
Alfie TJ, Wasfy JH, Kazi DS, Januzzi JL, Bellows BK, Cohen LP. Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review. Circulation: Population Health and Outcomes. 2026;19(7). doi:10.1161/circoutcomes.125.012989
BibTeX
@article{Alfie2026,
author = {Alfie, Tristan J and Wasfy, Jason H and Kazi, Dhruv S and Januzzi, James L and Bellows, Brandon K and Cohen, Laura P},
title = {Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review},
journal = {Circulation: Population Health and Outcomes},
year = {2026},
volume = {19},
number = {7},
doi = {10.1161/circoutcomes.125.012989}
}
EUVIMED